Journal of Neuro-Oncology

, 105:135 | Cite as

Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity

  • Harsha Prasada Lashkari
  • Srdjan Saso
  • Lucas Moreno
  • Thanos Athanasiou
  • Stergios Zacharoulis
Topic Review


Low grade gliomas (LGG) contribute to 50% of all central nervous tumors in children and 15% of all gliomas in adults. Temozolomide (TMZ) is an oral alkylating agent with activity in high and LGG. Various regimens of TMZ are currently in use. We attempted to assess the impact of different TMZ regimens on the treatment of LGG. A systematic review of the literature identified all the studies published in Pubmed, EMBASE and Cochrane databases which met the inclusion criteria. The primary outcome measure was the impact of different TMZ regimens on the 12 month progression-free survival (PFS) rates of patients diagnosed with progressive LGG. Secondary outcome measures looked at the ability of the three regimens to elicit an objective response and the associated toxicity. Statistical pooling and calculation of weighted mean average of each proportion (WMAP) was conducted using a random-effects model. 18 studies (736 patients) were analyzed. PFS at 12 months revealed a WMAP of 0.61 (95% CI 0.44–0.78) for regimen A, 0.59 (0.28–0.89) for regimen B, and 0.91 (95% CI 0.83–0.99) for regimen C (Regimen A—200 mg/m2/day for 5 days, repeated every 4 weeks; B—75 mg/m2/day for 21 days repeated every 4 weeks; C—75 mg/m2/day for 7 weeks with 4 weeks of every 11 weeks). In terms of objective response, WMAP were 0.19 (95% 0.13–0.25), 0.27 (95% CI 0.15–0.39) and 0.21 (95% CI 0.10–0.32) for regimen A, B, C respectively. When analyzing hematological toxicity, WMAPs were 0.14 (95% 0.11–0.18), 0.35 (0.14–0.56) and 0.23 (95% CI 0.03–0.43). The bulk of evidence originates from the standard 5 day/month regimen A but with a lack of comparative studies. Analysis revealed significant heterogeneity. Although there is possibly an indication that metronomic regimens of TMZ result in better PFS and response rate when compared to the conventional standard 5 day regimen, insufficient available data and study heterogeneity preclude any safe conclusions. Well designed randomized controlled clinical trials are needed to establish the efficacy of metronomic regimens of TMZ in LGGs.


Low grade gliomas (LGG) Children Temozolomide Metronomic chemotherapy 


  1. 1.
    Peterson K, DeAngelis LM (2001) Weighing the benefits and risks of radiation therapy for low-grade glioma. Neurology 56(10):1255–1256PubMedGoogle Scholar
  2. 2.
    Postma TJ, Klein M, Verstappen CC, Bromberg JE, Swennen M, Langendijk JA, Taphoorn MJ, Scheltens P, Slotman BJ, van der Ploeg HM, Aaronson NK, Heimans JJ (2002) Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology 59(1):121–123PubMedGoogle Scholar
  3. 3.
    Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86(5):747–754PubMedCrossRefGoogle Scholar
  4. 4.
    Vera K, Djafari L, Faivre S, Guillamo JS, Djazouli K, Osorio M, Parker F, Cioloca C, Abdulkarim B, Armand JP, Raymond E (2004) Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol 15(1):161–171PubMedCrossRefGoogle Scholar
  5. 5.
    Nagasubramanian R, Dolan ME (2003) Temozolomide: realizing the promise and potential. Curr Opin Oncol 15(6):412–418PubMedCrossRefGoogle Scholar
  6. 6.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRefGoogle Scholar
  7. 7.
    Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58(19):4363–4367PubMedGoogle Scholar
  8. 8.
    Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP (1993) Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67(6):1299–1302PubMedCrossRefGoogle Scholar
  9. 9.
    Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20(9):2388–2399PubMedCrossRefGoogle Scholar
  10. 10.
    Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 4(1):39–43PubMedGoogle Scholar
  11. 11.
    Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88(7):1004–1011PubMedCrossRefGoogle Scholar
  12. 12.
    National Cancer Institute Common Terminology Criteria for Adverse Events (2010) Accessed 17 June 2011
  13. 13.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535PubMedCrossRefGoogle Scholar
  14. 14.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012PubMedCrossRefGoogle Scholar
  15. 15.
    The Cochrane Library (2005) Cochrane handbook for systematic reviews of interventions 4.2.5 (updated May 2005)Google Scholar
  16. 16.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMedGoogle Scholar
  17. 17.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRefGoogle Scholar
  18. 18.
    Egger M, Smith G, Dg A (1995) Systematic reviews in healthcare: meta-analysis in context. BMJ Books, LondonGoogle Scholar
  19. 19.
    Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7(8):889–894PubMedCrossRefGoogle Scholar
  20. 20.
    Gururangan S, Fisher MJ, Allen JC, Herndon JE, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS (2007) Temozolomide in children with progressive low-grade glioma. Neuro Oncol 9(2):161–168PubMedCrossRefGoogle Scholar
  21. 21.
    Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15):3133–3138PubMedCrossRefGoogle Scholar
  22. 22.
    Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15(1):330–337PubMedCrossRefGoogle Scholar
  23. 23.
    Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T (2006) Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106(8):1759–1765PubMedCrossRefGoogle Scholar
  24. 24.
    Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM (2009) Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol 11(1):59–68PubMedCrossRefGoogle Scholar
  25. 25.
    Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer 110(7):1542–1550PubMedCrossRefGoogle Scholar
  26. 26.
    Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14(12):1722–1726PubMedCrossRefGoogle Scholar
  27. 27.
    Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21(4):646–651PubMedCrossRefGoogle Scholar
  28. 28.
    Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA (2008) Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 89(2):179–185PubMedCrossRefGoogle Scholar
  29. 29.
    van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht C, Allgeier A, Gorlia T (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21(13):2525–2528PubMedCrossRefGoogle Scholar
  30. 30.
    van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De BN, Baron B (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14(4):599–602PubMedCrossRefGoogle Scholar
  31. 31.
    Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bartschi E, Buettner UW, Roelcke U (2009) Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 95(1):87–93PubMedCrossRefGoogle Scholar
  32. 32.
    Chamberlain MC (2008) Temozolomide for recurrent low-grade spinal cord gliomas in adults. Cancer 113(5):1019–1024PubMedCrossRefGoogle Scholar
  33. 33.
    Everhard S, Kaloshi G, Criniere E, Ouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60(6):740–743PubMedCrossRefGoogle Scholar
  34. 34.
    Kaloshi G, ouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68(21):1831–1836PubMedCrossRefGoogle Scholar
  35. 35.
    Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM (2007) Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 49(6):808–811PubMedCrossRefGoogle Scholar
  36. 36.
    Kuo DJ, Weiner HL, Wisoff J, Miller DC, Knopp EA, Finlay JL (2003) Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 25(5):372–378PubMedCrossRefGoogle Scholar
  37. 37.
    Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D (2007) Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82(3):281–288PubMedCrossRefGoogle Scholar
  38. 38.
    van den Bent MJ, Afra D, de WO, Ben HM, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490):985–990Google Scholar
  39. 39.
    Baumert BG, Stupp R (2008) Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy. Ann Oncol 19(Suppl 7):vii217–vii222PubMedCrossRefGoogle Scholar
  40. 40.
    Friedman HS, Krischer JP, Burger P, Oakes WJ, Hockenberger B, Weiner MD, Falletta JM, Norris D, Ragab AH, Mahoney DH Jr (1992) Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 10(2):249–256PubMedGoogle Scholar
  41. 41.
    Friedman HS, Lovell S, Rasheed K, Friedman AH (1998) Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for The Brain Tumor Center at Duke. Med Pediatr Oncol 31(1):16–18PubMedCrossRefGoogle Scholar
  42. 42.
    Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76(5):741–745PubMedCrossRefGoogle Scholar
  43. 43.
    Prados MD, Edwards MS, Rabbitt J, Lamborn K, Davis RL, Levin VA (1997) Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J.Neurooncol 32(3):235–241PubMedCrossRefGoogle Scholar
  44. 44.
    Ater J, Holmes E, Zhou T, Mazewaski C, Roberts W, Vezina G et al (2008) Results of COG protocol A9952: a randomised phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. NeuroOncol 10:451–452Google Scholar
  45. 45.
    Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23(1):35–61PubMedCrossRefGoogle Scholar
  46. 46.
    Stupp R, Gander M, Leyvraz S, Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2(9):552–560PubMedCrossRefGoogle Scholar
  47. 47.
    EORTC Brain Tumour Group (2010) Phase III intergroup study of radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with newly diagnosed anaplastic oligodendroglioma or anaplastic mixed glioma with chromosomal co-deletions of 1p and 19q. In: (internet), EORTC, Brussels. EORTC protocol 26081–22086. Accessed 17 June 2011
  48. 48.
    European Organization for Research and Treatment of Cancer (2011) Primary chemotherapy with temozolomide versus radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study. In: (internet). National Library of Medicine (US) 2000, Bethesda. NLM identifier NCT00182819. Accessed 17 June 2011
  49. 49.
    Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta MP (2011). RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 29(15 Suppl): ASCO meeting abstracts:2006Google Scholar
  50. 50.
    Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 321(1):265–275PubMedCrossRefGoogle Scholar
  51. 51.
    Kreklau EL, Kurpad C, Williams DA, Erickson LC (1999) Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo. J Pharmacol Exp Ther 291(3):1269–1275PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Harsha Prasada Lashkari
    • 1
  • Srdjan Saso
    • 2
  • Lucas Moreno
    • 3
  • Thanos Athanasiou
    • 4
  • Stergios Zacharoulis
    • 5
  1. 1.The Royal Marsden Hospital NHS Foundation TrustSuttonUK
  2. 2.Division of Surgery and CancerInstitute of Reproductive & Developmental Biology, Imperial College London, Hammersmith Hospital CampusLondonUK
  3. 3.Drug DevelopmentThe Royal Marsden Hospital NHS Foundation TrustSuttonUK
  4. 4.Department of Cardiothoracic SurgeryNational Heart and Lung Institute, Imperial College London. The Hammersmith HospitalLondonUK
  5. 5.Children and Young People’s UnitThe Royal Marsden Hospital NHS Foundation TrustSuttonUK

Personalised recommendations